EcoDrugPlus

Bradykinin Receptor B2

Ensembl ID : ENSAPEG00000016635
Gene Symbol: BDKRB2
1 Cross references
231 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSAPEG00000016759
Gene Symbol: BDKRB2
2 Cross references
182 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSAPEG00000016583
Gene Symbol: BDKRB2
1 Cross references
230 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSAPEG00000016724
Gene Symbol: BDKRB2
1 Cross references
231 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSAPEG00000016700
Gene Symbol: BDKRB2
1 Cross references
230 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSAPEG00000016650
Gene Symbol: BDKRB2
1 Cross references
231 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1c Subunit

Ensembl ID : ENSAPEG00000004540
Gene Symbol: CACNA1C
1 Cross references
215 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1d Subunit, A

Ensembl ID : ENSAPEG00000019495
Gene Symbol: CACNA1DA
1 Cross references
212 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1f Subunit

Ensembl ID : ENSAPEG00000022410
Gene Symbol: CACNA1FB
1 Cross references
177 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1s Subunit, A

Ensembl ID : ENSAPEG00000003723
Gene Symbol: CACNA1SA
1 Cross references
196 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1s Subunit, B

Ensembl ID : ENSAPEG00000001852
Gene Symbol: CACNA1SB
1 Cross references
196 Possible Orthologues:

Calcium Channel, Voltage-Dependent, N Type, Alpha 1b Subunit, A

Ensembl ID : ENSAPEG00000014062
Gene Symbol: CACNA1BA
1 Cross references
211 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).